Isoprinosine in multiple sclerosis treatment: a preliminary study.
Isoprinosine, a drug enhancing the cellular immunity, was administered to 11 patients with multiple sclerosis (MS) for a period of 60 days. Kurtzke's Disability Status Scale was evaluated in all the patients before the starting of the therapy and after 60 days and after 14 months of follow-up. 11 MS patients were taken as a control group and were treated with prednisone for the same period of time. No significant difference in the clinical course of the disease between the two groups of patients after the therapeutical trial was observed. CSF examination showed IgG oligoclonal bands in all the cases; no modification of the CSF IgG profile was found after the therapy in those patients in whom the lumbar puncture was performed after the follow-up period.
D000328:Adult; D000917:Antibody Formation / Q000187:drug effects; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007074:Immunoglobulin G / Q000134:cerebrospinal fluid; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D011241:Prednisone / Q000627:therapeutic use
D007074:Immunoglobulin G; D007288:Inosine; D011241:Prednisone; D007542:Inosine Pranobex